

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Madaline Chirica, et al.

Application No.: not yet known

Filed: Herewith

For: MAMMALIAN RECEPTOR  
PROTEINS; RELATED  
REAGENTS AND METHODS

Examiner: not yet known

Art Unit: not yet known

Conf. No.: not yet known

"Express Mailing" mailing label number EL 982 851 390 US

Date of Deposit: September / 8 , 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

by:

  
MELANIE LYONS

**INFORMATION DISCLOSURE STATEMENT**

Sir:

The materials as listed in the attached Form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB/08 listing references AA-AQ.

All references listed on the attached form PTO/SB/08 have been previously cited either by Applicants or the Examiner in the parent application, U.S. Patent Application No. 09/853,180, filing date May 10, 2001, and copies should be available there. As such, these references will not be provided absent a specific request.


Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached Form PTO/SB/08. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe that no fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: September 18, 2003

By:   
Sheela Mohan-Peterson  
Registration No.: 41,201  
Attorney for Applicants

***Customer No. 28008***

DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not yet known
				Filing Date	Herewith
				First Named Inventor	Madaline CHIRICA
				Art Unit	Not yet known
				Examiner Name	Not yet known
Sheet	1	of	3	Attorney Docket Number	DX01074B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	AA	Kim E. BARRETT, <u>Baillieres Clin. Gastroenterol.</u> , 10(1):1-15, March 1996. "Cytokines: sources, receptors and signalling"	
	AB	J. Fernando BAZAN, <i>et al.</i> , <u>Nature</u> , 379:591, February 15, 1996. "A newly defined interleukin-1?"	
	AC	J. BRISCOE, <i>et al.</i> , <u>Philos. Trans. R. Soc. Lond. B Biol. Sci.</u> 351(1336):167-71, February 29, 1996. "JAKs, STATs and signal transduction in response to the interferons and other cytokines"	
	AD	Irwin M. CHAIKEN & William V. WILLIAMS, <u>Trends Biotechnol.</u> , 14(10):369-75, October 1996. "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design"	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not yet known
				Filing Date	Herewith
				First Named Inventor	Madaline CHIRICA
				Art Unit	Not yet known
				Examiner Name	Not yet known
Sheet	2	of	3	Attorney Docket Number	DX01074B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	AE	THOMAS J. GONDA & RICHARD J. D'ANDREA, <u>Blood</u> , 89(2):355-369, January 15, 1997. "Activating mutations in cytokine receptors: implications for receptor function and role in disease"	
	AF	PETER C. HEINRICH, <i>et al.</i> , <u>Biochem. J.</u> , 334 (Pt 2):297-314, September 1, 1998. "Interleukin 6-type cytokine signalling through the gp130/Jak/STAT pathway"	
	AG	JEFFREY M. HERZ, <i>et al.</i> , <u>J. Recept. Signal Transduct. Res.</u> , 17(5):671-776, September 1997. "Molecular approaches to receptors as targets for drug discovery"	
	AH	M. HIBI, <i>et al.</i> , <u>GenBank</u> , Accession No. M57230, January 6, 1995. Definition: Human membrane glycoprotein gp130 mRNA, complete cds.	
	AI	JAMES N. IHLE, <i>et al.</i> <u>Stem Cells</u> , 15 (Suppl 1):105-11, 1997. "Jaks and Stats in cytokine signaling"	
	AJ	DAVID E. LEVY, <u>Cytokine Growth Factor Rev.</u> , 8(1):81-90, March 1997. "The house that JAK/STAT built"	
	AK	S. LOK, <i>et al.</i> , <u>Database EMBL Online!</u> , Accession Number, AF178684, September 10, 1999. Definition: Homo sapiens class I cytokine receptor (zcytor5) mRNA, complete cds.	
	AL	NEELA PATEL, <i>et al.</i> , <u>J Biol Chem.</u> , 271(48):30386-30391, November 29, 1996. "Functional replacement of cytokine receptor extracellular domains by leucine zippers"	
	AM	DAVID H. PRESKY, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 93:14002-14007, November 1996. "A functional interleukin 12 receptor complex is composed of two b-type cytokine receptor subunits"	
	AN	D.H. PRESKY, <i>et al.</i> , <u>GenBank</u> , Accession No. U64198, November 28, 2000. Definition: Human IL-12 receptor beta2 mRNA, complete cds.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.